Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders (THERAMAG)

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders:

Anti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the peripheral nervous system. Its prevalence is around 1/100000 and to date, no treatment has proven efficacy in this disease, including rituximab in 2 Randomized Controlled Trails(RCTs).

Study Overview

• Status: Recruiting
• Conditions: Anti-MAG Neuropathy
• Intervention / Treatment: Drug: Placebo infusion; Drug: Premedications; Drug: Rituximab infusion

Detailed Description

However these trials have included unselected anti-MAG patients and methodological issues have been raised.

In COFRAMAG study, the largest cohort worldwide of anti-MAG patients, predictors of clinical response to rituximab were identified through analysis of 92 treated patients: shorter disease duration and anti-MAG titre above 10000 BTU. Thus this study will focus on rituximab efficacy in a subset of patients with disease duration of less than 2 years and anti-MAG titre above 10000 Buhlmann Titer Units (BTU). The investigators selected Inflammatory Rasch-built Overall Disability Scale (I-RODS) as primary outcome measure because its responsiveness was proven higher than INCAT/ Overall Neuropathy Limitation Score (ONLS) scales to detect clinical meaningful changes in newly treated patients with inflammatory neuropathies.

• Study Type: Interventional
• Enrollment (Estimated): 90
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Anne-Laure KAMINSKY, MD; Phone Number: +33 (0)4 77 82 95 10; Email: a.laure.kaminsky@chu-st-etienne.fr
• Study Contact Backup: Name: Carine LABRUYERE, CRA; Phone Number: +33 (0)4 77 12 04 69; Email: carine.labruyere@chu-st-etienne.fr

Study Locations

• France
  • Brest, France, 29200
    • Not yet recruiting
    • CHU Brest - La cavale blanche
    • Principal Investigator: Jean-Baptiste NOURY, MD
  • Grenoble, France, 38700
    • Not yet recruiting
    • CHU Grenoble - La tronche
    • Principal Investigator: Martial MALLARET, MD
  • Lille, France, 59037
    • Not yet recruiting
    • CHU Lille - Roger Salengro
    • Principal Investigator: Celine Tard, MD
  • Limoges, France, 87170
    • Not yet recruiting
    • CHU Limoges - Dupuytren
    • Principal Investigator: Laurent MAGY, PhD
  • Lyon, France, 69002
    • Not yet recruiting
    • HCL Lyon
    • Principal Investigator: Juliette SVAHN
  • Marseille, France, 13915
    • Not yet recruiting
    • CHU La Timone - APHM
    • Principal Investigator: Shahram Attarian, PhD
  • Nancy, France, 54035
    • Not yet recruiting
    • CHU Nancy- Hôpital central
    • Principal Investigator: Maud MICHAUD, MD
  • Nice, France, 06031
    • Not yet recruiting
    • CHU Nice - Pasteur
    • Principal Investigator: Sabrina SACCONI, MD
  • Paris, France, 75651
    • Not yet recruiting
    • Aphp Pitie Salpetriere
    • Principal Investigator: Thierry MAISONOBE, MD
  • Paris, France, 94270
    • Not yet recruiting
    • APHP - Kremlin-Bicêtre
    • Principal Investigator: Andoni ECHANIZ-LAGUNA, PhD
  • Saint-Étienne, France
    • Recruiting
    • CHU de Saint-Etienne
    • Principal Investigator: Anne-Laure KAMINSKY, MD
  • Strasbourg, France, 67091
    • Not yet recruiting
    • CHU Strasbourg - Hautepierre
    • Principal Investigator: Jean-Baptiste CHANSON, MD
  • Toulouse, France, 31059
    • Not yet recruiting
    • CHU Toulouse - Pierre-Paul Riquet
    • Principal Investigator: Pascal CINTAS, MD
  • Tours, France, 37044
    • Not yet recruiting
    • CHU Tours - Bretonneau
    • Principal Investigator: Philippe CORCIA, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Disease duration of 24 months or less and documented clinical worsening (clinical or ENMG or disability) over the past 12 months
• IgM gammopathy, either MGUS or Waldenstrom Macroglobulinemia (WM)
• Demyelinating polyneuropathy according to European Federation of Neurological Societies/Peripheral Nerve Society guidelines for chronic inflammatory demyelinating polyneuropathy on nerve conduction studies.
• Anti-MAG titre of 10 000 BTU or more
• Total INCAT score of 1 point or more at baseline
• Absence of immunoglobulin treatment within 3 months prior to inclusion.
• Absence of immunosuppressive therapy within 6 months prior to inclusion, including steroid therapy of 2 months or more as part of the management of neuropathy.
• Negative β-human chorionic gonadotropin (HCG) in women of childbearing potential
• Women of childbearing potential must agree to use contraception for 365 days following administration of rituximab.

Exclusion Criteria:

• - Unable to give informed consent
• History of severe allergic or anaphylactic reaction to chimeric monoclonal antibody
• Hypersensitivity known to one of the compounds of polaramine or methylprednisolone
• Previous treatment with rituximab
• Diseases known to cause polyneuropathy (e.g. diabetes, uncontrolled thyroid disease, vitamin B1 or B12 deficiency, renal (GFR < 60ml ml/min/1,73 m2- Modification of Diet in Renal Disease (MDRD) formula) or liver disorder, myeloma, amyloidosis, cryoglobulinemia)
• Indication of specific immunosuppressive therapy for WM
• Significant uncontrolled disease at baseline such as cardiovascular (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine or gastrointestinal or any other significant disease that may prevent patient from participating in the study
• Congestive heart failure (NYHA III or IV)
• Known active bacterial, viral, fungal mycobacterial infection
• History or known presence of recurrent or chronic infection (e.g. viral hepatitis, HIV syphilis, tuberculosis).
• History of cancer, including solid tumors and haematological malignancies (except basal cell and in situ squamous carcinoma of the skin, in situ carcinoma of the cervix of the uterus that have been excised and resolved, with documented clear margins on pathology)
• History of alcohol (more than two drinks a day for a woman, more than 4 glasses a day for a man [World Health Organization (WHO) definition]) or other drug abuse within 6 months prior to randomization
• History or currently active primary or secondary immunodeficiency
• White blood cell count < 1500/mm3 or platelet count < 75 000/mm3
• Angle closure glaucoma,
• Urinary retention related to urethroprostatic disorders,
• Uncontrolled psychotic disorders,
• Severe liver failure,
• Recent vaccination with live vaccines (<3months) and vaccination with live virus vaccines is not recommended during the overall study period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group. They will have the same premedications prior to rituximab or placebo infusions: IV Dexchlorpheniramine Maleate IV: 10 mg; IV Methylprednisolone: 40 mg; PO Paracetamol : 1 gram	Drug: Placebo infusion; 2 infusions of placebo at a 2 week interval.; Other Names: Sodium chloride (NaCl); Drug: Premedications; Premedications prior to rituximab or placebo infusions: IV Dexchlorpheniramine Maleate IV: 10 mg; IV Methylprednisolone: 40 mg; PO Paracetamol : 1 gram
Active Comparator: Rituximab; Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group. They will have the same premedications prior to rituximab or placebo infusions: IV Dexchlorpheniramine Maleate IV: 10 mg; IV Methylprednisolone: 40 mg; PO Paracetamol : 1 gram	Drug: Premedications; Premedications prior to rituximab or placebo infusions: IV Dexchlorpheniramine Maleate IV: 10 mg; IV Methylprednisolone: 40 mg; PO Paracetamol : 1 gram; Drug: Rituximab infusion; 2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).; Other Names: Mabthera

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
I-RODS score	Clinical response defined as a 4 points (or more) change of I-RODS between baseline and 12 months. I-RODS is a 24-item patient-reported outcome measure which maximum score is 48. It is a linearly weighted scale that specifically captures activity and social participation limitations in patients with inflammatory neuropathies, including Monoclonal Gammopathy of Unknown Significance (MGUS) related polyneuropathies.	Baseline and 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Inflammatory Neuropathy Cause and Treatment (INCAT) disability score	The INCAT (Inflammatory Neuropathy Cause and Treatment) disability score is a measure of activity limitation with minimum score at 0 and maximum at 10.	Months: 0, 6, 12
Six minute walk test	Six minute walk test will be realized.	Months : 0, 6, 12
Timed 25- foot walk (FW) test	The T25-FW is a quantitative test of mobility and performance of leg function based on a timed outward journey of 25 steps, and a timed return journey of 25 steps. The score for the T25-FW is the average of the two completed trials	Months : 0, 6, 12
9 hole peg test	The nine hole peg test is a standardized, quantitative assessment used to measure finger dexterity. Scores are based on the time taken to complete the test activity, recorded in seconds	Months : 0, 6, 12
ENMG sensory sum score	ENMG sensory sum score will be realized.	Months : 0, 6, 12
Score Motor unit number index (MUNIX)	Score MUNIX will be realised.	Months : 0, 6, 12
the anti-MAG antibody titre.	To study the correlation between the clinical response and the evolution of the anti-MAG antibody titre.	Months : 0, 6, 12
ElectroNeuroMyography (ENMG)	An ENMG will be realized.	Months : 0, 6, 12
Incidence of Treatment-Emergent Adverse Events of Rituximab	Consideration of adverse effects of Rituximab	Months : 0, 6, 12

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Saint Etienne
• Collaborators: Ministry of Health, France
• Investigators: Principal Investigator: Anne-Laure KAMINSKY, MD, CHU de Saint-Etienne

Study record dates

Study Major Dates

• Study Start (Actual): June 29, 2023
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: November 16, 2021
• First Submitted That Met QC Criteria: November 16, 2021
• First Posted (Actual): November 30, 2021

Study Record Updates

• Last Update Posted (Actual): October 16, 2023
• Last Update Submitted That Met QC Criteria: October 13, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: placebo; Rituximab; Neuropathy; Anti-MAG; I-RODS
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Rituximab
• Other Study ID Numbers: 19PH226; 2021-000009-25 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No